In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

Vertex Pharmaceuticals (VRTX ... we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, stretching ...

This was the stock's second consecutive day of losses.

Most investors are happy if a stock doubles within four or five years. Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders should be ecstatic. Its share price has skyrocketed 140% over the last ...

As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise ...

And we're really excited to have the Vertex IR team with us ... neurons and because of that we don't have any central nervous system effects. So you avoid all the side effects of opioids including ...

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time, the Dow ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other biotech stocks. As we have mentioned in our article, “10 Best ...